Clinical Scorecard: Lactate Biomarker May Predict Outcomes in Cardiogenic Shock
At a Glance
| Category | Detail |
|---|---|
| Condition | Cardiogenic Shock |
| Key Mechanisms | Reduced cardiac output, systemic hypoperfusion, adrenergic stimulation, ischemia-reperfusion injury, systemic inflammation, mitochondrial dysfunction, impaired hepatic or renal clearance. |
| Target Population | Patients with cardiogenic shock |
| Care Setting | Intensive care and emergency settings |
Key Highlights
- Admission lactate levels are associated with shock severity and mortality.
- Lactate thresholds of 3 to 3.5 mmol/L indicate higher short-term mortality risk.
- Serial lactate monitoring reflects metabolic recovery and response to therapy.
- Early lactate clearance is a strong predictor of survival post-VA-ECMO initiation.
- Lactate should be interpreted as a dynamic biomarker reflecting metabolic stress and clearance.
Guideline-Based Recommendations
Diagnosis
- Use admission lactate levels to assess shock severity.
Management
- Monitor lactate levels serially to guide treatment and assess recovery.
Monitoring & Follow-up
- Track lactate clearance within the first 24 hours for survival prediction.
Risks
- Persistent hyperlactatemia despite adequate device flow is associated with poor outcomes.
Patient & Prescribing Data
Patients undergoing treatment for cardiogenic shock, including those receiving VA-ECMO.
Epinephrine may elevate lactate levels, complicating clinical interpretation.
Clinical Best Practices
- Integrate lactate values with clinical context for accurate assessment.
- Consider trajectory-based lactate assessment for risk stratification.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
